FOXR2 and central nervous system neoplasm: We first looked at the downstream effects of FOXR2 activation in CNS tumors at the DNA methylation level by comparing the DNA methylome profiles of tumors with FOXR2 overexpression in our cohort (n = 30 with sufficient data quality) with those of DMGs without FOXR2 activation (n = 25).